In the mouse studies, we tested RBAC at 2 doses (2.5 mg/kg and 5 mg/kg and saline in parallel groups) in two genotypes (WT and Fmr1 KO mice) and humans with FXS received a single 30 mg RBAC dose (approximately equivalent to mouse 5 mg/kg) or placebo in random order with a washout period between dosing. The gene discussed is FMR1; the disease is fragile X syndrome.